JOURNEY MEDICAL CORP (DERM)

US48115J1097 - Common Stock

5.78  +0.23 (+4.14%)

After market: 5.78 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to DERM. DERM was compared to 194 industry peers in the Pharmaceuticals industry. DERM has a medium profitability rating, but doesn't score so well on its financial health evaluation. DERM does not seem to be growing, but still is valued expensively.



Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year DERM has reported negative net income.
DERM had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: DERM reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: DERM reported negative operating cash flow in multiple years.

1.2 Ratios

DERM's Return On Assets of 1.29% is amongst the best of the industry. DERM outperforms 83.33% of its industry peers.
DERM's Return On Equity of 7.47% is amongst the best of the industry. DERM outperforms 86.98% of its industry peers.
Looking at the Return On Invested Capital, with a value of 5.42%, DERM belongs to the top of the industry, outperforming 82.29% of the companies in the same industry.
Industry RankSector Rank
ROA 1.29%
ROE 7.47%
ROIC 5.42%
ROA(3y)-26.13%
ROA(5y)-11.5%
ROE(3y)-99.32%
ROE(5y)-23.41%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

DERM's Profit Margin of 1.09% is amongst the best of the industry. DERM outperforms 82.81% of its industry peers.
DERM has a better Operating Margin (2.74%) than 78.13% of its industry peers.
DERM's Operating Margin has declined in the last couple of years.
DERM has a Gross Margin of 66.79%. This is in the better half of the industry: DERM outperforms 70.31% of its industry peers.
In the last couple of years the Gross Margin of DERM has declined.
Industry RankSector Rank
OM 2.74%
PM (TTM) 1.09%
GM 66.79%
OM growth 3Y-57.52%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.45%
GM growth 5Y-7.36%

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), DERM is destroying value.
The number of shares outstanding for DERM has been increased compared to 1 year ago.
DERM has less shares outstanding than it did 5 years ago.
The debt/assets ratio for DERM has been reduced compared to a year ago.

2.2 Solvency

DERM has an Altman-Z score of 0.60. This is a bad value and indicates that DERM is not financially healthy and even has some risk of bankruptcy.
DERM has a Altman-Z score (0.60) which is comparable to the rest of the industry.
A Debt/Equity ratio of 1.75 is on the high side and indicates that DERM has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.75, DERM is doing worse than 78.13% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.75
Debt/FCF N/A
Altman-Z 0.6
ROIC/WACC0.61
WACC8.92%

2.3 Liquidity

A Current Ratio of 1.36 indicates that DERM should not have too much problems paying its short term obligations.
DERM has a worse Current ratio (1.36) than 77.60% of its industry peers.
DERM has a Quick Ratio of 1.08. This is a normal value and indicates that DERM is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of DERM (1.08) is worse than 78.65% of its industry peers.
Industry RankSector Rank
Current Ratio 1.36
Quick Ratio 1.08

More info and screens

3

3. Growth

3.1 Past

DERM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.00%.
DERM shows a small growth in Revenue. In the last year, the Revenue has grown by 7.48%.
The Revenue has been growing by 13.34% on average over the past years. This is quite good.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-121.25%
Revenue 1Y (TTM)7.48%
Revenue growth 3Y21.15%
Revenue growth 5Y13.34%
Sales Q2Q%-57.64%

3.2 Future

Based on estimates for the next years, DERM will show a very negative growth in Earnings Per Share. The EPS will decrease by -33.51% on average per year.
DERM is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.24% yearly.
EPS Next Y-561.58%
EPS Next 2Y27.74%
EPS Next 3Y-33.51%
EPS Next 5YN/A
Revenue Next Year-27.73%
Revenue Next 2Y-0.36%
Revenue Next 3Y0.24%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DERM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DERM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

80.73% of the companies in the same industry are more expensive than DERM, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 15.13

4.3 Compensation for Growth

A cheap valuation may be justified as DERM's earnings are expected to decrease with -33.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.74%
EPS Next 3Y-33.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DERM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JOURNEY MEDICAL CORP

NASDAQ:DERM (11/29/2024, 2:20:01 PM)

After market: 5.78 0 (0%)

5.78

+0.23 (+4.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap86.06M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.29%
ROE 7.47%
ROCE
ROIC
ROICexc
ROICexgc
OM 2.74%
PM (TTM) 1.09%
GM 66.79%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.19
Health
Industry RankSector Rank
Debt/Equity 1.75
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.36
Quick Ratio 1.08
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-561.58%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)7.48%
Revenue growth 3Y21.15%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y